Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

source extracted confidence: high 2026-04-09
#diabetes-mellitus-type-2 #humans #hypolipidemic-agents #lipids #resveratrol

Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Zhao et al., 2019 | Obesity (Silver Spring) | Meta Analysis

Citation

Zhao Hang, Song An, ... Ma Huijuan. Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2019-Jan;27(1):94-102. doi:10.1002/oby.22348

Abstract

OBJECTIVE: Few studies have considered the effect of resveratrol on blood lipid levels, and the results of these studies are inconsistent. In this study, the first meta-analysis on the effect of resveratrol on blood lipid levels in patients with type 2 diabetes was conducted. METHODS: This study used keywords such as type 2 diabetes, total cholesterol, triglyceride (TG), high-density lipoprotein, low-density lipoprotein, and resveratrol and their abbreviations, free words, and related words to search PubMed, Cochrane Library, and Embase. The Cochrane risk of bias tool was used to evaluate the risk of bias, and Review Manager 5.3 and Stata 13.0 were used for data merging and statistical analysis. RESULTS: Ten randomized controlled trials involving a total of 363 patients with type 2 diabetes were included in the analysis. The results show that longer resveratrol intervention time (≥6 months) can reduce TG levels. But resveratrol increased total cholesterol in patients within obesity range. In type 2 diabetes patients with obesity and in those who took lipid-lowering drugs, resveratrol increased low-density lipoprotein levels. CONCLUSIONS: Resveratrol can improve TG in patients with type 2 diabetes.

Key Findings

Ten randomized controlled trials involving a total of 363 patients with type 2 diabetes were included in the analysis. The results show that longer resveratrol intervention time (≥6 months) can reduce TG levels. But resveratrol increased total cholesterol in patients within obesity range. In type 2 diabetes patients with obesity and in those who took lipid-lowering drugs, resveratrol increased low-density lipoprotein levels.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population type 2 diabetes was
Sample Size 363
Age Range See abstract
Condition diabetes

MeSH Terms

  • Diabetes Mellitus, Type 2
  • Humans
  • Hypolipidemic Agents
  • Lipids
  • Resveratrol

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09